Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.10
+0.02 (+0.15%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,071,511
Open
13.07
Bid (Size)
12.90 (1)
Ask (Size)
13.32 (1)
Prev. Close
13.08
Today's Range
13.03 - 13.12
52wk Range
12.77 - 16.39
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
June 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Performance
YTD
-8.65%
-8.65%
1 Month
-1.58%
-1.58%
3 Month
-10.03%
-10.03%
6 Month
-5.07%
-5.07%
1 Year
-18.58%
-18.58%
More News
Read More
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
June 11, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
Via
InvestorPlace
Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
June 03, 2024
Via
Benzinga
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
June 03, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
May 19, 2024
Via
Talk Markets
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
May 15, 2024
Via
Benzinga
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
May 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13, 2024
Via
Benzinga
Why Is AC Immune (ACIU) Stock Up 45% Today?
May 13, 2024
Via
InvestorPlace
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Via
Investor's Business Daily
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
May 09, 2024
Via
Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
May 09, 2024
Via
InvestorPlace
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
May 09, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
April 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
April 26, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
Via
Investor's Business Daily
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
April 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
April 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.